Avoiding the COVID-19 Wave of Securities Litigation

In the latest a long time, public organizations have been contending with an maximize in securities litigation and personal organizations have been contending with an maximize in Securities and Trade Commission investigations. COVID-19 threatens to accelerate this trend. Firm executives should be thorough to disclose any material impact the pandemic is acquiring on their small business to minimize the danger of so-called “event-driven” securities litigation.  

In “event-driven” litigation, the litigation does not occur from an accounting restatement as a substitute, there is normally an “event” and a subsequent inventory drop that plaintiffs allege has arisen from that function.

Some the latest examples include litigation introduced against Chipotle and Johnson & Johnson. In Chipotle’s scenario, buyers claimed that the business should have disclosed the circumstances surrounding meals-borne disease outbreaks. In Johnson & Johnson’s scenario, buyers claimed that the business intentionally concealed that its talc and talcum powder goods were being contaminated with asbestos.  

As the plaintiff’s bar is at any time much more artistic in acquiring methods to provide securities litigation, what might securities litigation with regard to COVID-19 glimpse like? Two circumstances that have already been submitted supply some indicator. 

Cruise line. A securities course action was brought on behalf of a course consisting of all persons who ordered or in any other case obtained the publicly traded securities of a cruise line from February 20, 2020, through March 12, 2020. It is alleged that the defendants built untrue and/or misleading statements and/or failed to disclose that: (1) the company was employing profits strategies of giving consumers with unproven and/or blatantly untrue statements about COVID-19 to entice consumers to invest in cruises, hence endangering the lives of both equally consumers and crew members and (2) as a outcome, defendants’ statements pertaining to the company’s small business and functions were being materially untrue and misleading and/or lacked a acceptable foundation at all pertinent times. 

Pharmaceutical company. A securities course action was introduced on behalf of all people who ordered or in any other case acquired the typical inventory of a pharmaceutical business between February 14, 2020, and March nine, 2020 (the “class period”). It is alleged that during the class period, defendants capitalized on popular COVID-19 fears by falsely claiming that the business had produced a vaccine for COVID-19.  

In the 1st make any difference, plaintiffs are looking for to hold the defendants liable for allegedly giving consumers with unproven statements or lies about COVID-19 to maximize small business. In the second make any difference, plaintiffs are looking for to hold the defendants liable for allegedly lying about their ability and timeframe to produce a vaccine for COVID-19.  

Both require alleged perform by the defendants that has a incredibly specific backlink to COVID-19. Future securities litigation may include matters that occur from failure to comply with advice issued by the SEC. 

In advice issued on March 25, 2020, the SEC’s division of corporation finance stated that it is checking how organizations are disclosing the consequences and challenges of COVID-19 on their enterprises, financial condition, and results of functions. Questions that the SEC questioned organizations to look at incorporated, but were being not constrained to: 

(1) How has COVID-19 impacted your financial condition and the results of functions?  In light of changing traits and the overall financial outlook, how do you be expecting COVID-19 to impact your foreseeable future working results and around-and-extended-expression financial condition?  Do you be expecting that COVID-19 will impact foreseeable future functions in different ways than how it affected the recent period of time? 

Table of Contents

Toggle

Based on the advice offered by the SEC, it is not hard to imagine securities litigation becoming filed against organizations that know COVID-19 will negatively impact profits but do not share that data with the general public in an expedient fashion.

(2) How has COVID-19 impacted your cash and financial assets, like your overall liquidity situation and outlook?   

(three) How do you be expecting COVID-19 to impact assets on your equilibrium sheet and your ability to well timed account for all those assets?   

(four) Do you anticipate any material impairments (e.g., with respect to goodwill, intangible assets, extended-lived assets, appropriate of use assets, expenditure securities), raises in allowances for credit history losses, restructuring prices, other bills, or alterations in accounting judgments that have had or are fairly possible to have a material impact on your financial statements? 

(five) Have COVID-19-connected circumstances these kinds of as distant work arrangements adversely affected your ability to maintain functions, like financial reporting methods, internal command above financial reporting, and disclosure controls and procedures?   

(6) Have you knowledgeable troubles in utilizing small business continuity designs or do you foresee requiring material expenditures to do so?   

(7) Do you be expecting COVID-19 to materially impact the desire for your goods or expert services? 

(8) Do you anticipate a material adverse impact of COVID-19 on the offer chain or the techniques utilised to distribute your goods or expert services?   

(nine) Are journey restrictions and border closures anticipated to have a material impact on your ability to run and achieve small business plans? 

The SEC encouraged organizations to disclose information that enables investors to evaluate the recent and anticipated impact of COVID-19 as a result of the eyes of administration and to proactively revise and update disclosures as specifics and circumstances modify. 

The SEC also reminded organizations that they can use the protected harbors in Section 27A of the Securities Act and Section 21E of the Trade Act by giving forward-wanting data in an work to maintain buyers knowledgeable about material developments, like known traits or uncertainties pertaining to COVID-19. 

For that reason, primarily based on the advice offered by the SEC, it is not hard to imagine securities litigation becoming filed against organizations that know COVID-19 will negatively impact profits but do not share that data with the general public in an expedient fashion.  

Securities litigation could also be submitted against organizations that know that small business functions are likely to be materially negatively affected by the financial impact of social distancing and/or the ability to get the products required to make or distribute their goods or expert services, but do not make that information general public expertise in a well timed style. 

The SEC may also investigate organizations and individuals who act in these kinds of a fashion as described above, specially if there is evidence of individuals trading in the company’s securities prior to the general public dissemination of material data. These potential investigations could not be constrained to general public organizations.  

The dealings of personal organizations and their executives have become an improved region of aim for the SEC, especially with respect to precise and possible buyers. As the SEC has the authority to investigate all organizations that request to elevate cash from U.S. buyers, personal organizations would be sensible to comply with the SEC’s advice as properly. 

As the troubles in these unprecedented times continue to evolve, general public and personal organizations should supply material data to their buyers and potential buyers as it unfolds and make guaranteed to update all those disclosures as the specifics and circumstances about their organizations change. Failure to do so could outcome in securities litigation and investigations by the SEC.  

To assistance minimize this danger on a pre-declare basis and with any statements that could occur from COVID-19, it is vital for insurance plan brokers and their general public and personal business consumers to work with a carrier that can supply administrators’ and officers’ insurance protection and has an expert claims staff that is closely watching COVID-19’s impact on securities litigation and SEC investigations. 

Timothy Vazquez is assistant vice president, claims practice leader-directors & officers, of QBE North The usa. 

COVID-19, SEC, securities litigation